Cumulus Oncology and leadXpro AG have signed a research collaboration focused on the discovery and development of small molecules targeting an undisclosed and novel cancer-focused G protein-coupled receptor (GPCR). The resulting IP of the collaboration wil be licensed into a newly created Cumulus company.
This collaboration will use the core expertise of both companies to create an initial high-value, lead programme. LeadXpro will use its structural biology expertise, combining proprietary technology in protein structure determination, coupled with biophysical characterisation and computational modelling, to generate novel compounds. Cumulus Oncology brings a team of successful life science entrepreneurs with deep oncology sector knowledge and a recognised track record in translational oncology drug development.
A GPCR portfolio company, created by Cumulus Oncology, focused on novel GPCR targets on tumours and the tumour microenvironment, will have the option to license the Lead compound series as well as resulting intellectual property from the research collaboration. Under the license terms, leadXpro will retain an economic interest in the Lead compound series.
Clare Wareing, Founder and CEO of Cumulus Oncology, said: “Given the recent and parallel progress in both understanding the role of GPCRs in cancer, as well as the technological advances that enable a more robust characterisation of these important membrane signal transducers, we believe there is significant medical and commercial potential for GPCRs in the oncology field. LeadXpro have in-depth expertise in the characterisation of membrane proteins with a strong track record in GPCRs. With their structural biology expertise, innovative platform technology and track record of success, we believe they are the ideal partner to accelerate the discovery of small molecule modulators of a novel GPCR target.”
Michael Hennig, Co-founder, CEO and Chairman of the Board at leadXpro, said: “We are very pleased to be working with Cumulus Oncology. The team have an impressive track record in the successful translation of early-stage science into commercially and medically successful cancer therapeutics. Cumulus Oncology’s approach to identifying and validating early-stage opportunities and targets coupled with both capital and expert oncology drug development resources make them an ideal partner.”
(Press release / SK)
0Comments
More news about
Please login or sign up to comment.
Commenting guidelines